Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Jul 1, 2025 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 2, 2025 05:00PM
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress May 14, 2025 04:05PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 1, 2025 05:00PM
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC Apr 28, 2025 08:00AM
View Older Stories

Apr 23, 2025 04:05PM Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
Apr 1, 2025 05:30PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 26, 2025 04:05PM Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Mar 25, 2025 04:40PM Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
Mar 15, 2025 11:25AM Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Mar 3, 2025 05:00PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 3, 2025 08:00AM Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Feb 24, 2025 04:05PM Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Feb 3, 2025 05:42PM Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan 29, 2025 07:09AM Zentalis Pharmaceuticals (ZNTL) Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Jan 29, 2025 07:00AM Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Jan 28, 2025 04:07PM Zentalis Pharmaceuticals (ZNTL) Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
Jan 28, 2025 04:05PM Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
Jan 9, 2025 07:00AM Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
Jan 2, 2025 04:53PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 12, 2024 07:04AM Zentalis Pharmaceuticals (ZNTL) Announces Management Appointments
Dec 12, 2024 07:00AM Zentalis Pharmaceuticals Announces Key Management Appointments
Dec 2, 2024 04:35PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 13, 2024 08:01AM Zentalis Pharmaceuticals (ZNTL) Announces Executive Leadership Changes
Nov 13, 2024 08:00AM Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
Nov 1, 2024 07:04PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 16, 2024 07:01AM Zentalis Pharmaceuticals (ZNTL) Announces FDA Lifted Partial Clinical Hold on Azenosertib Studies
Sep 16, 2024 07:00AM Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
Sep 9, 2024 07:00AM Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
Sep 3, 2024 04:40PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 9, 2024 07:00AM Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
Aug 1, 2024 06:00PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 1, 2024 06:00PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 18, 2024 07:00AM Zentalis Pharmaceuticals (ZNTL) Provides Update on Azenosertib Clinical Development Program
Jun 18, 2024 07:00AM Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
Jun 3, 2024 06:00PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 30, 2024 07:00AM Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 29, 2024 07:03AM Zentalis Pharmaceuticals (ZNTL) Appoints Luke Walker to its Board
May 29, 2024 07:00AM Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
May 23, 2024 05:02PM Zentalis Pharmaceuticals (ZNTL) to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma
May 23, 2024 05:01PM Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meet
May 14, 2024 07:00AM Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
May 7, 2024 07:00AM Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
May 1, 2024 05:30PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 2, 2024 04:05PM Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Apr 1, 2024 05:30PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 1, 2024 06:00PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 28, 2024 07:00AM Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Feb 27, 2024 07:00AM Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Feb 13, 2024 07:00AM Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
Feb 1, 2024 05:00PM Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 25, 2024 07:04AM Zentalis Pharmaceuticals (ZNTL) Announces Management Changes
Jan 25, 2024 07:00AM Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
Jan 8, 2024 07:05AM Immunome Inc. (IMNM) Exclusively Licenses Zentalis (ZNTL) ROR1 Antibody-Drug Conjugate
Jan 8, 2024 07:00AM Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
View Older Stories